MedTrace Logo

Mechanisms of Lorcaserin for Smoking Cessation

NCT04396834 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-03-20

Study results available
· View outcomes & findings →

Summary

Identifying new medication options is critical for curbing the health burdens of cigarette smoking. Currently approved smoking cessation medications act on nicotinic receptors, and additional work is needed to identify medications with alternate pharmacological targets. Based on evidence that the serotonin system plays a role in nicotine consumption and relapse, this study will examine whether a selective serotonin medication alters smoking-related behaviors and responses to cigarette smoking under controlled conditions, informing its potential utility for smoking cessation.

Conditions

  • Tobacco Use Disorder
  • Smoking Cessation

Interventions

DRUG

Lorcaserin Oral Tablet

Lorcasering 10mg Oral Tablet (BID)

DRUG

Placebo oral tablet

Placebo Oral Tablet (BID)

Sponsors & Collaborators

  • The Mind Research Network

    lead OTHER

Principal Investigators

  • Christian Hendershot, Ph.D. · The Mind Research Network

  • Eric Claus, Ph.D. · The Mind Research Network

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-04
Primary Completion
2020-02-26
Completion
2020-02-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04396834 on ClinicalTrials.gov